Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IT-4 F is an acceptor-donor-acceptor (A-D-A) type molecule that is assembled into water-dispersible nanoparticles (IT-4 F NPs). These nanoparticles exhibit near-infrared (NIR) absorption and fluorescence, functioning as phototheranostics. Under NIR laser irradiation, IT-4 F NPs efficiently convert photon energy into heat (photothermal conversion efficiency of 42.8%) and generate reactive oxygen species, specifically singlet oxygen (quantum yield of 31.5%) and superoxide anion. This dual action enables NIR fluorescence imaging-guided photothermal therapy (PTT) and photodynamic therapy (PDT). The therapeutic effect involves inducing immunogenic cell death and PANoptosis in tumor cells, leading to the inhibition of tumor growth and metastasis, and stimulating a robust immune response characterized by increased infiltration of CD8+ T cells, CD4+ T cells, dendritic cells, and a reduction in immunosuppressive cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IT-4 F.